Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Wuxi Biologics (Cayman) ( (HK:2269) ) has issued an update.
Wuxi Biologics has approved the grant of 288,441 restricted shares at no purchase cost to 21 employees under its Restricted Share Award Scheme, with a market reference price of HK$29.94 per share on the grant date. The award vests in four equal annual installments over four years, reinforcing long-term employee retention and aligning staff interests with shareholder value.
The scheme includes a clawback mechanism allowing the board to lapse unvested awards and recover vested shares or equivalent value in cases of termination for cause or criminal offenses involving integrity or honesty. The grant is purely time-based with no performance targets, signaling a focus on retention and stability of key talent rather than performance-linked incentives in the company’s equity compensation strategy.
The most recent analyst rating on (HK:2269) stock is a Buy
with a HK$50.00 price target.
To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock,
see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. is a contract development and manufacturing organization in the biopharmaceutical industry, providing end-to-end services for the discovery, development, and production of biologics. The company focuses on serving global pharmaceutical and biotechnology clients seeking outsourced biologics manufacturing and related solutions.
Average Trading Volume: 28,142,950
Technical Sentiment Signal: Sell
Current Market Cap: HK$125.8B
See more insights into 2269 stock on TipRanks’ Stock Analysis page.
